YU43996A - Upotreba duloksetina za proizvodnju leka i njegova farmaceutska kompozicija - Google Patents

Upotreba duloksetina za proizvodnju leka i njegova farmaceutska kompozicija

Info

Publication number
YU43996A
YU43996A YU43996A YU43996A YU43996A YU 43996 A YU43996 A YU 43996A YU 43996 A YU43996 A YU 43996A YU 43996 A YU43996 A YU 43996A YU 43996 A YU43996 A YU 43996A
Authority
YU
Yugoslavia
Prior art keywords
duloxetine
application
pharmaceutical composition
medicament production
compound
Prior art date
Application number
YU43996A
Other languages
English (en)
Inventor
Harrison Heiligenstein John
Coleman Laguzza Bennett
Marc Paul Steven
Dennis Tollefson Gary
Original Assignee
Eli Lilly Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9525909.9A external-priority patent/GB9525909D0/en
Application filed by Eli Lilly Company filed Critical Eli Lilly Company
Publication of YU43996A publication Critical patent/YU43996A/sh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Opisano je korišćenje jedinjenja formule (I) u kojoj X predstavlja C1-C4 alkiltio a Y jeC1-C2 alkil, ili njen stereoizomer ili farmaceutski prihvatljiva so, za proizvodnju leka za tretiranje poremećaja nedostatka pažnje/hiperaktivnosti, koji se sastoji od tog jedinjenja i farmaceutskog nosača. Jedinjenje koje za ovu svrhu koristi je N-metil-3-(2-metiltiofenoksi)-3-fenilpropilamin ili njegov stereoizomer ili njegova farmaceutski prihvatljiva so.
YU43996A 1995-07-24 1996-07-23 Upotreba duloksetina za proizvodnju leka i njegova farmaceutska kompozicija YU43996A (sh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US137395P 1995-07-24 1995-07-24
US634995P 1995-11-08 1995-11-08
GBGB9525909.9A GB9525909D0 (en) 1995-12-19 1995-12-19 Treatment of attention-defecit/hyperactivity disorder

Publications (1)

Publication Number Publication Date
YU43996A true YU43996A (sh) 1999-06-15

Family

ID=27268037

Family Applications (1)

Application Number Title Priority Date Filing Date
YU43996A YU43996A (sh) 1995-07-24 1996-07-23 Upotreba duloksetina za proizvodnju leka i njegova farmaceutska kompozicija

Country Status (14)

Country Link
EP (1) EP0756869A3 (sh)
JP (1) JPH11510143A (sh)
KR (1) KR19990035817A (sh)
CN (1) CN1195287A (sh)
AU (1) AU709704B2 (sh)
CA (1) CA2227410A1 (sh)
CZ (1) CZ16798A3 (sh)
EA (1) EA000856B1 (sh)
IL (1) IL122984A0 (sh)
MX (1) MX9800589A (sh)
NO (1) NO980251D0 (sh)
NZ (1) NZ313076A (sh)
WO (1) WO1997003665A1 (sh)
YU (1) YU43996A (sh)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA56257C2 (uk) * 1997-09-23 2003-05-15 Елі Ліллі Енд Компані Спосіб лікування неадекватної визивної поведінки
JP2001517628A (ja) * 1997-09-23 2001-10-09 イーライ・リリー・アンド・カンパニー 注意欠陥／多動障害の治療法
UA57107C2 (uk) * 1997-09-23 2003-06-16 Елі Ліллі Енд Компані Спосіб лікування розладу поведінки
US6586427B2 (en) 1998-04-09 2003-07-01 Pharmacia & Upjohn Company Treatments for nervous disorders
EA200001049A1 (ru) * 1998-04-09 2001-04-23 Фармация Энд Апджон Компани Новые способы лечения нервных расстройств
ES2315525T3 (es) 2002-08-23 2009-04-01 Eli Lilly And Company Derivados de 2-(feniltiometil)-morfolina para uso como inhibidores selectivos de la recaptacion de norepinefrina.
GB0219687D0 (en) * 2002-08-23 2002-10-02 Lilly Co Eli Benzyl morpholine derivatives
WO2004103356A2 (en) * 2003-05-15 2004-12-02 Eli Lilly And Company Treatment of emotional dysregulation
EP1660185A2 (en) * 2003-08-27 2006-05-31 Eli Lilly And Company Treatment of stuttering and other communication disorders with norepinephrine reuptake inhibitors
CN111728971A (zh) 2012-09-18 2020-10-02 奥斯拜客斯制药有限公司 D6-四苯喹嗪固体口服剂型、化合物、及其药物组合物、制备及治疗方法
EP3610890A1 (en) 2012-11-14 2020-02-19 The Johns Hopkins University Methods and compositions for treating schizophrenia
CN114788824A (zh) 2015-03-06 2022-07-26 奥斯拜客斯制药有限公司 氘代丁苯那嗪或包含氘代丁苯那嗪的组合物
JP2020029447A (ja) * 2018-06-25 2020-02-27 大原薬品工業株式会社 腸溶性高分子及び抗付着剤を含有する顆粒

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4956388A (en) * 1986-12-22 1990-09-11 Eli Lilly And Company 3-aryloxy-3-substituted propanamines
US5114976A (en) * 1989-01-06 1992-05-19 Norden Michael J Method for treating certain psychiatric disorders and certain psychiatric symptoms
US5281624A (en) * 1991-09-27 1994-01-25 Eli Lilly And Company N-alkyl-3-phenyl-3-(2-substituted phenoxy) propylamines and pharmaceutical use thereof
DK0537915T3 (da) * 1991-09-27 1995-11-27 Lilly Co Eli N-alkyl-3-phenyl-3-(2-alkylthiophenoxy)propylaminer som inhibitorer for epinephrin
EP0591581B1 (en) * 1992-10-08 1995-08-09 Eli Lilly And Company N-Alkyl-3-phenyl-3-(2-alkylthiophenoxy)propylamines
CA2134038C (en) * 1994-06-16 1997-06-03 David Taiwai Wong Potentiation of drug response
US5508276A (en) * 1994-07-18 1996-04-16 Eli Lilly And Company Duloxetine enteric pellets
ZA958725B (en) * 1994-10-20 1997-04-16 Lilly Co Eli Treatment of disorders with duloxetine
US5696168A (en) * 1995-07-24 1997-12-09 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder

Also Published As

Publication number Publication date
EA199800152A1 (ru) 1998-08-27
CA2227410A1 (en) 1997-02-06
KR19990035817A (ko) 1999-05-25
EP0756869A2 (en) 1997-02-05
WO1997003665A1 (en) 1997-02-06
EA000856B1 (ru) 2000-06-26
AU709704B2 (en) 1999-09-02
NO980251L (no) 1998-01-20
MX9800589A (es) 1998-04-30
AU6506196A (en) 1997-02-18
IL122984A0 (en) 1998-08-16
CN1195287A (zh) 1998-10-07
EP0756869A3 (en) 1999-06-16
NZ313076A (en) 1999-11-29
CZ16798A3 (cs) 1998-11-11
JPH11510143A (ja) 1999-09-07
NO980251D0 (no) 1998-01-20

Similar Documents

Publication Publication Date Title
YU43996A (sh) Upotreba duloksetina za proizvodnju leka i njegova farmaceutska kompozicija
AP9801169A0 (en) N-hydroxy-B-sulfonyl propionamide derivatives.
SE9504661D0 (sv) New compounds
PT814796E (pt) Uso de um farmaco r-aine numa composicao protectora para o tratamento do cancro colorectal
TR199903191T2 (xx) Vorikonazol i�eren ila� form�lasyonlar�.
YU13695A (sh) Upotreba 2-fenil-3-aroilbenzotiofena i njihove farmaceutske formulacije
MY132705A (en) Novel compounds with analgesic effect
DE502004011581D1 (de) Verwendung von rotigotin zur behandlung von depressionen
ES2183841T3 (es) Formas de dosificacion para administrar un farmasco en una formulacion lquidid.
AR037517A1 (es) Derivados de naftiridinas, un proceso para su preparacion, composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento para el tratamiento de una enfermedad inflamatoria
BR0111913A (pt) Análogos de gabapentina para distúrbios do sono
ATE206611T1 (de) Verwendung von mangiferin oder seinen derivaten zur kosmetischen anwendung
NZ502853A (en) Treatment of conduct disorder with a norepinephrine reuptake inhibitor such as tomoxetine
DE69940557D1 (de) Ein hydrokolloid und einen celluloseether enthaltende tablette mit verzögerter freisetzung
SE9900961D0 (sv) Novel compounds
SE9802208D0 (sv) Novel compounds
SE0102440D0 (sv) New compound
GEP20043227B (en) 5HT1 Antagonists for Antidepressant Therapy
DE60035133D1 (de) Pharmazeutische zusammensetzungen mit wundheilender und anti-komplementärer wirkung die ein dextranderivat enthalten
SE9504662D0 (sv) New compounds
BR0108980A (pt) Aplicação e formulação farmacêuticas compreendendo inibidor de reabsorção de norepinefrina
ATE525078T1 (de) Kyberdrug als autovakzine mit immunregulierenden wirkungen
GEP20043231B (en) Resorcinol Composition
RS50523B (sr) Farmaceutska kompozicija koja sadrži cink-hijaluronat kompleks za lečenje multiple skleroze
SE9900190D0 (sv) New compounds